Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects
Erectile Dysfunction
About this trial
This is an interventional treatment trial for Erectile Dysfunction
Eligibility Criteria
Inclusion Criteria: ≥ 65 years old; Male≥50kg,femal≥45kg, Body mass index should be between 18 and 30 kg/m2 (inclusive); No major organ dysfunction;normal heart, liver and kidney function; Physical examination, vital signs examination, laboratory examination (blood routine, urine routine, blood biochemistry), 12 lead ECG, Abdominal ultrasound, chest X-ray results were normal or abnormal but investigator judged suitable for participating in this trial; Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent Exclusion Criteria: Allergies to test preparations, any of their ingredients, and related preparations; With allergies or allergic diseases; Surgical condition or condition that may significantly affect ADME of the drug, urgical condition or condition that may pose a hazard if the subject participating in the study Myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, congestive heart failure, severe arrhythmias, cerebrovascular accidents, including transient ischemic attack within 3 months before inclusion; Taken any of drugs(Inhibits or induces liver metabolism) within 2 weeks before inclusion;administered with Nitrate/Nitric oxide (NO) donors。 With a history of the following ocular diseases: nonvascular anterior ischemic optic neuropathy (NAION), abnormal color vision, hereditary retinopathy (e.g. Retinitis pigmentosa), and macular degeneration; A history of sudden decrease or loss of hearing; A history of postural hypotension; Blood loss ≥400 mL within 3 months before inclusion; Participated in other drug clinical trials or medical devices clinical trials within 3 months before administration; Drink alcohol at least 2 times a day or more than 14 times a week in the 6 months prior to enrollment or alcoholics(Drink alcoholics defined as 125 mL of wine, 220 mL of beer, or liquor50mL; Alcoholism is defined as 5 or more drinks in approximately 2 hours) ; A history of drug use or have been screened positive for drug abuse; Smoked more than 10 cigarettes a day within 6 months prior to inclusion; hepatitis B surface antigen (HBsAg),hepatitis C virus antibody,treponema pallidum antibody,Human immunodeficiency virus antibody (HIV)positive; Other factors that the investigator considered inappropriate for the study.
Sites / Locations
- Shanghai Xuhui Central Hospital
Arms of the Study
Arm 1
Experimental
TPN171H
5 mg TPN171H tablets,single dose,oral